揭开隐藏的风险:来自FAERS数据库的阿布拉克桑相关不良事件的最新十年分析
Yue-Chen Zhao1,2, Xin Li3, Chao-Qun Wang4
1Department of Radiation Oncology, The Second Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
International journal of nanomedicine
|November 19, 2024
概括
这项研究分析了10,310份Abraxane不良事件报告,确定了常见和新的副作用,如神经病变和罕见的血管事件. 持续的警对于安全的Abraxane (纳米粒子蛋白结合的帕克利塔塞尔) 使用至关重要.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
背景情况:
- 艾布拉克桑 (纳米粒子蛋白结合的帕克利塔塞尔) 是治疗乳腺癌,肺癌和胰腺癌的关键化疗.
- 虽然有效,但Abraxane与需要监测的不良事件 (AE) 有关.
研究的目的:
- 为了评估Abraxane的不良事件 (AE) 概况.
- 利用来自FDA不良事件报告系统 (FAERS) 的2004年1月至2023年12月的最新数据.
主要方法:
- 从FAERS数据库中提取了与Abraxane相关的AE数据.
- 计算报告赔率比率 (ROR) 和比例报告比率 (PRR) 来评估AE协会.
主要成果:
- 确定了10,310份阿布拉克桑AE报告.
- 最常见的副作用是:血液/淋巴 (ROR 6.44),肝胆道 (ROR 3.16),感染 (ROR 1.45),胃肠道 (ROR 1.42) 的情况.
- 观察到新的副作用:类似于硬化皮的反应 (ROR 95.4),血管伪动脉瘤破裂 (ROR 87.71).
结论:
- FAERS分析提供了对Abraxane的最新安全信息.
- 强调需要持续的药物监测和进一步调查特定的副作用.
- 强调一个强大的营销后监测系统对阿布拉克桑安全性的重要性.
相关概念视频
Pharmacovigilance
774
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
774
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


